PYC Therapeutics Ltd
ASX:PYC
Intrinsic Value
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. [ Read More ]
The intrinsic value of one
PYC
stock under the Base Case scenario is
0.123
AUD.
Compared to the current market price of 0.092 AUD,
PYC Therapeutics Ltd
is
Undervalued by 25%.
PYC's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
PYC or that its price is influenced by factors unrelated to fundamentals.
PYC Therapeutics Ltd's market capitalization is 429.3m AUD.
PYC stock price is 0.092 AUD.
PYC stock price (0.092 AUD) is 25% less than its Intrinsic Value (0.123 AUD).
PYC. Open DCF Valuation
PYC stock price (0.092 AUD) is 25% less than its Relative Value (0.123 AUD). Open Relative Valuation
PYC has upside potential of 278% compared to the average analyst price target.
Open Wall St Estimates
PYC's Revenue has grown by an exceptional 60% over the past 12 months.
PYC's Revenue is forecast to grow at a rate of 28% per year over the next 3 years.
PYC's ROE (Return on Equity) has significantly decreased in the last 3 years from -26% to -83%, and is approaching profitability.
PYC's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -222% to -294%, and is approaching profitability.
PYC has negative Operating Income for the last twelve months.
PYC has negative Net Income for the last twelve months.
PYC's ROE (Return on Equity) for the past 12 months is negative and is equal to -83%.
PYC's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -294%.
PYC has negative Free Cash Flow for the last twelve months.
PYC's Revenue has been growing by an exceptional 99% per year for the last 3 years.
PYC's D/E (Debt to Equity) is very low and is equal to 0.01.
PYC's short-term assets (34m AUD) exceed its short-term liabilties (9m AUD).
PYC has negative three-year average ROE (Return on Equity): -50%. The company is not efficient at transforming stockholders' equity into net income.
PYC has negative three-year average ROIC (Return on Invested Capital): -294%. The company is not efficient at using invested capital to generate operating income.
PYC's long-term assets (40m AUD) exceed its long-term liabilties (10m AUD).
PYC has negative Net Debt. This means that the company has more cash and short-term investments (25m AUD) than debt (220k AUD).
PYC's Altman Z-Score is very high and is equal to 25.55.
PYC earns more than enough operating income (-21m AUD) to safely cover interest payments on its debt (-52k AUD).
Valuation Backtest
PYC Therapeutics Ltd
Run backtest to discover the historical profit from buying and selling
PYC
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
PYC Therapeutics Ltd
Balance Sheet Decomposition
PYC Therapeutics Ltd
| Current Assets | 34.4m |
| Cash & Short-Term Investments | 25.4m |
| Receivables | 8.7m |
| Other Current Assets | 314.4k |
| Non-Current Assets | 5.4m |
| PP&E | 1.2m |
| Intangibles | 4.2m |
| Current Liabilities | 8.6m |
| Accounts Payable | 7.4m |
| Accrued Liabilities | 897.8k |
| Other Current Liabilities | 324.4k |
| Non-Current Liabilities | 1.2m |
| Long-Term Debt | 219.8k |
| Other Non-Current Liabilities | 1m |
Earnings Waterfall
PYC Therapeutics Ltd
|
Revenue
|
21.5m
AUD
|
|
Operating Expenses
|
-42.8m
AUD
|
|
Operating Income
|
-21.2m
AUD
|
|
Other Expenses
|
-395.6k
AUD
|
|
Net Income
|
-21.6m
AUD
|
Free Cash Flow Analysis
PYC Therapeutics Ltd
PYC Profitability Score
Profitability Due Diligence
PYC Therapeutics Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
PYC Therapeutics Ltd's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
PYC Solvency Score
Solvency Due Diligence
PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
PYC Therapeutics Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PYC Price Targets Summary
PYC Therapeutics Ltd
According to Wall Street analysts, the average 1-year price target for
PYC
is 0.348 AUD
with a low forecast of 0.299 AUD and a high forecast of 0.405 AUD.
Shareholder Return
PYC Price
PYC Therapeutics Ltd
| Average Annual Return | 64% |
| Standard Deviation of Annual Returns | 109.25% |
| Max Drawdown | -73% |
| Market Capitalization | 429.3m AUD |
| Shares Outstanding | 4 666 080 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
PYC Therapeutics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one
PYC
stock under the Base Case scenario is
0.123
AUD.
Compared to the current market price of 0.092 AUD,
PYC Therapeutics Ltd
is
Undervalued by 25%.
You don't have any saved screeners yet
